



April 30, 2026

Company name: ROHTO Pharmaceutical Co., Ltd.

Representative: Hidetoshi Segi,

President and Representative Director

(Code: 4527 TSE Prime)

Contact: Masaya Saito, Vice President and CFO

(TEL: 06-6758-8223)

Notice of Receipt of Shareholder Proposals

Rohto Pharmaceutical Co., Ltd. (the “Company”) hereby announces that the Company has received two shareholder proposals: one dated April 17, 2026 (hereinafter referred to as "Shareholder Proposal 1") from AVI JAPAN OPPORTUNITY TRUST PLC, a shareholder of the Company, and another dated April 20, 2026 (hereinafter referred to as "Shareholder Proposal 2") from LONGCHAMP SICAV, a shareholder of the Company, regarding the 90th Ordinary General Meeting of Shareholders scheduled to be held on June 24, 2026.

The Company’s Board of Directors will disclose its views on Proposal 1 and Proposal 2 promptly once they have been determined after careful consideration and deliberation.

Note

[Shareholder Proposal 1]

1. Proposing Shareholder

AVI JAPAN OPPORTUNITY TRUST PLC

2. Agenda Item in Shareholder Proposal 1

Dismissal of one director

[Shareholder Proposal 2]

1. Proposing Shareholder

LONGCHAMP SICAV

2. Agenda Item in Shareholder Proposal 2

(1) Amendment to the Articles of Incorporation regarding the establishment of a Strategic

Rohto Pharmaceutical Co., Ltd.

Review Committee

- (2) Amendment to the Articles of Incorporation regarding the decision-making body for dividends from surplus and other distributions.
- (3) Repurchase of Shares
- (4) Approval of compensation amount for the restricted stock compensation plan
- (5) Amendment to the Articles of Incorporation regarding the composition of outside directors
- (6) Amendment to the Articles of Incorporation regarding measures to realize management that is mindful of the cost of capital and share price
- (7) Amendment to the Articles of Incorporation regarding the record date for the ordinary general meeting of shareholders